Skip to main content
SpringerLink
Log in

Endotoxin

Pathogenetische Bedeutung bei der Sepsis

  • Sepsis—“Fakten und Mythen“
  • Published:
Der Anaesthesist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Angus DC, Birmingham MC, Balk RA et al. (2000) E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283:1723–1730

    CAS  PubMed  Google Scholar 

  2. Bauer M, Rensing H, Ziegenfuss T (1998) Anästhesie und perioperative Immunfunktion. Anaesthesist 47:538–556

    Article  CAS  PubMed  Google Scholar 

  3. Baumgartner JD (1991) Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect Dis Clin North Am 5:915–927

    CAS  PubMed  Google Scholar 

  4. Bohrer H, Qiu F, Zimmermann T et al. (1997) Role of NFkappaB in the mortality of sepsis. J Clin Invest 100:972–985

    PubMed  Google Scholar 

  5. Boivin A, Mesrobeanu L, Mesrobeanu I (1933) Technique pour la preparation des polysaccharides micobiens specific. Compt Rend Soc Biol 113:490–492

    CAS  Google Scholar 

  6. Bone RC, Balk RA, Fein AM et al. (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 23:994–1006

    CAS  PubMed  Google Scholar 

  7. Bunnell E, Lynn M, Habet K et al. (2000) A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 28:2713–2720

    CAS  PubMed  Google Scholar 

  8. Calandra T, Glauser MP, Schellekens J, Verhoef J (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 158:312–319

    CAS  PubMed  Google Scholar 

  9. Centanni E (1894) Untersuchungen über das Infektionsfieber. Das Fiebergift der Bacterien. Dtsch Med Wochenschr 20:148–150

    Google Scholar 

  10. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock. Chest 99:169–175

    CAS  PubMed  Google Scholar 

  11. Deuren M van, Brandtzaeg P, Meer JW van der (2000) Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13:144–166

    PubMed  Google Scholar 

  12. Deventer S van, Buller HR, Cate J ten, Sturk A, Pauw W (1988) Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1:605–609

    PubMed  Google Scholar 

  13. Devleeschouwer MJ, Cornil MF, Dony J (1985) Studies on the sensitivity and specificity of the Limulus amebocyte lysate test and rabbit pyrogen assays. Appl Environ Microbiol 50:1509–1511

    CAS  PubMed  Google Scholar 

  14. Elin RJ, Robinson RA, Levine AS, Wolff SM (1975) Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. N Engl J Med 293:521–524

    CAS  Google Scholar 

  15. Elsbach P, Weiss J (1998) Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 10:45–49

    CAS  PubMed  Google Scholar 

  16. Farmer TW (1948) Jarisch-Herxheimer reaction in early syphilis: treatment with crystaline penicillin G. JAMA 138:480–485

    Google Scholar 

  17. Fekade D, Knox K, Hussein K, Melka A, Lalloo DG, Coxon RE, Warrell DA (1996) Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 335:311–315

    CAS  PubMed  Google Scholar 

  18. Frevert CW, Matute-Bello G, Skerrett SJ, Goodman RB, Kajikawa O, Sittipunt C, Martin TR (2000) Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 164:5439–5445

    CAS  PubMed  Google Scholar 

  19. Galloway RE, Levin J, Butler T et al. (1977) Activation of protein mediators of inflammation and evidence for endotoxemia in Borrelia recurrentis infection. Am J Med 63:933–938

    CAS  PubMed  Google Scholar 

  20. Giroir BP, Quint PA, Barton P et al. (1997) Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 350:1439–1443

    CAS  PubMed  Google Scholar 

  21. Greenman RL, Schein RM, Martin MA et al. (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266:1097–1102

    Article  CAS  PubMed  Google Scholar 

  22. Grundmann U, Rensing H, Adams HA, Falk S, Wendler O, Ebinger N, Bauer M (2000) Endotoxin desensitization of human mononuclear cells after cardiopulmonary bypass: role of humoral factors. Anesthesiology 93:359–369

    CAS  PubMed  Google Scholar 

  23. Harbarth S, Ferriere K, Hugonnet S, Ricou B, Suter P, Pittet D. (2002) Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 137:1353–1359

    Article  PubMed  Google Scholar 

  24. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM (1995) Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 154:6529–6532

    CAS  PubMed  Google Scholar 

  25. Haziot A, Ferrero E, Kontgen F et al. (1996) Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 4:407–414

    CAS  PubMed  Google Scholar 

  26. Heagy W, Hansen C, Nieman K, Cohen M, Richardson C, Rodriguez JL, West MA (2000) Impaired ex vivo lipopolysaccharide-stimulated whole blood tumor necrosis factor production may identify „septic“ intensive care unit patients. Shock 14:271–276

    CAS  PubMed  Google Scholar 

  27. J5 study Group (1992) Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis 165:695–701

    PubMed  Google Scholar 

  28. Jackson JJ, Kropp H (1992) beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 165:1033–1041

    CAS  PubMed  Google Scholar 

  29. Kirsch EA, Barton RP, Kitchen L, Giroir BP (1996) Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 15:967–978

    CAS  PubMed  Google Scholar 

  30. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474

    CAS  PubMed  Google Scholar 

  31. Lepper PM, Held TK, Schneider EM, Bolke E, Gerlach H, Trautmann M (2002) Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 28:824–833

    Article  Google Scholar 

  32. Leturcq DJ, Moriarty AM, Talbott G, Winn RK, Martin TR, Ulevitch RJ (1996) Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 98:1533–1538

    CAS  PubMed  Google Scholar 

  33. Levin J, Bang FB (1968) Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh 19:186–197

    CAS  PubMed  Google Scholar 

  34. Levin M, Quint PA, Goldstein B et al. (2000) Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356:961–967

    CAS  PubMed  Google Scholar 

  35. Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327–2334

    CAS  PubMed  Google Scholar 

  36. Lyytikainen O, Lumio J, Sarkkinen H, Kolho E, Kostiala A, Ruutu P (2002) Nosocomial bloodstream infections in Finnish hospitals during 1999–2000. Clin Infect Dis 35:e14–19

    Article  CAS  PubMed  Google Scholar 

  37. Marra MN, Thornton MB, Snable JL, Wilde CG, Scott RW (1994) Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 22:559–565

    CAS  PubMed  Google Scholar 

  38. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121:1–5

    CAS  PubMed  Google Scholar 

  39. Michie HR, Manogue KR, Spriggs DR et al. (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486

    Google Scholar 

  40. Mock CN, Jurkovich GJ, Dries DJ, Maier RV (1995) Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg 130:1234–1240

    CAS  PubMed  Google Scholar 

  41. Opal SM, Yu RLJ (1998) Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions. Drugs 55:497–508

    CAS  PubMed  Google Scholar 

  42. Opal SM, Gluck T (2003) Endotoxin as a drug target. Crit Care Med 31:S57–64

    CAS  PubMed  Google Scholar 

  43. Opal SM, Scannon PJ, Vincent JL et al. (1999) Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180:1584–1589

    Article  CAS  PubMed  Google Scholar 

  44. Poltorak A, He X, Smirnova I et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088

    Article  CAS  PubMed  Google Scholar 

  45. Rensing H, Bauer M (2001) Multiorganversagen. Mechanismen, klinische Manifestation und Therapiestrategien. Anaesthesist 50:819–841

    Article  CAS  PubMed  Google Scholar 

  46. Rietschel ET, Brade H, Brade L et al. (1987) Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity. Prog Clin Biol Res 231:25–53

    CAS  PubMed  Google Scholar 

  47. Simpson AJ, Opal SM, Angus BJ et al. (2000) Differential antibiotic-induced endotoxin release in severe melioidosis. J Infect Dis 181:1014–1019

    CAS  PubMed  Google Scholar 

  48. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280–287

    Google Scholar 

  49. Suffredini AF, Harpel PC, Parrillo JE (1989) Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165–1172

    Google Scholar 

  50. The French National Registry of HA-1A (Centoxin) in septic shock (1994) A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 154:2484–2491

    Article  PubMed  Google Scholar 

  51. The Intravenous Immunoglobulin Collaborative Study Group (1992) Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:234–240

    PubMed  Google Scholar 

  52. Thomas LL, Sturk A, Kahle LH, Cate JW ten (1981) Quantitative endotoxin determination in blood with a chromogenic substrate. Clin Chim Acta 116:63–68

    Article  CAS  PubMed  Google Scholar 

  53. Trautmann M, Heinemann M, Zick R, Moricke A, Seidelmann M, Berger D (1998) Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis 17:754–760

    CAS  PubMed  Google Scholar 

  54. Ulevitch RJ (2001) New therapeutic targets revealed through investigations of innate immunity. Crit Care Med 29:S8–12

    CAS  PubMed  Google Scholar 

  55. Verbon A, Dekkers PE, Hove T ten et al. (2001) IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 166:3599–3605

    CAS  PubMed  Google Scholar 

  56. Ziegenfuss T, Wanner GA, Grass C et al. (1999) Mixed agonistic-antagonistic cytokine response in whole blood from patients undergoing abdominal aortic aneurysm repair. Intensive Care Med 25:279–287

    CAS  PubMed  Google Scholar 

  57. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225–1230

    CAS  PubMed  Google Scholar 

  58. Ziegler EJ, Fisher CJJ, Sprung CL et al. (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429–436

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Anästhesiologie und Intensivmedizin, Universitätskliniken des Saarlandes, Homburg/Saar

    H. Rensing

  2. Klinik für Anästhesiologie und Intensivmedizin, Universitätskliniken des Saarlandes, Kirrberger Straße, 66421 , Homburg/Saar

    H. Rensing

Authors
  1. H. Rensing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Rensing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rensing, H. Endotoxin. Anaesthesist 52 (Suppl 1), S7–S13 (2003). https://doi.org/10.1007/s00101-003-0587-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00101-003-0587-7

Search

Navigation